CClinicalTrials.gg
CompletedNCT03619564CKDODUpdated Feb 22, 2024

Chronic Kidney Disease Observational Database - Taiwan

An observational study in Chronic Kidney Insufficiency, sponsored by Fresenius Kabi. Completed at 9 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-02-22.

Sponsored by Fresenius Kabi · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the effect of a ketoanalogue supplemented very low protein diet on eGFR decline in chronic kidney disease compared to a low protein diet (0.6 g/kg, LPD) or no protein restriction.

Read the detailed description

An important part of care in chronic kidney disease is an adapted diet. Its most important aspect is protein restriction. The rationale for protein restriction is a reduction of uremic wastes. However, nutritional requirements for protein synthesis limit the maximum extent of protein restriction. To deal with these conflicting targets, a minimum protein intake supplemented with ketoanalogues of amino acids (supplemented very low protein diet, sVLPD) meets the protein needs while reducing uremic waste.

The aim of this explorative, observational study is to determine the effect of sVLPD on eGFR decline compared to a low protein diet (LPD) or no protein restriction.

Data collection The study uses only data from routine health care records. The transfer to the electronic case report form is done by center investigators.

Data entry is monitored monthly for completeness and plausibility. Missing or unusual data will be requested for completion or re-assessment.

In case of high loss to follow up (>10%), low follow up frequency (\<90% of patients with \<3 visits per year), or greater than 5% missing core data (age, gender, descent, height, weight, history of diabetes and hypertension, blood pressure, serum creatinin, dietary prescription, judgement of compliance), audit visits including source data verification and trainings may be done.

Primary analysis Direct comparison of patients receiving sVLPD or LPD is not meaningful due to the non-interventional design. It is expected that sVLPD patients will have a more advanced stage of CKD, most likely will have higher severity of disease and possibly may have different demographic baseline data. Furthermore, other well-known risk factors for progression of chronic kidney disease like the presence of diabetes mellitus or high blood pressure may affect eGFR decline.

A relevant amount of data is expected to be missing due to the observational nature and the use of data from clinical routine. Furthermore, missing data are unlikely to occur completely at random.

Therefore, missing data will not be imputed but they will be implicitly modeled by a mixed model: mean changes of eGFR from baseline will be analyzed using a restricted maximum-likelihood based repeated measures approach. Analyses will include the fixed, categorical effects of actual treatment, study center, gender, visit time, and baseline variables presence of smoking history, diabetes mellitus, hypertension, and baseline eGFR. Patient will be included as a random factor to the model. Significance tests will use a two-sided α = 0.05.

Secondary analyses Compliance, dietary counselling, use of a nutritional diary, primary diagnosis of CKD, diabetes mellitus, and vegetarian diet will be included to the model described before and analyzed for independent effects or effect modification of the diet.

The approach to the secondary analysis of development of serum urea is similar to the primary analysis.

Cox-regression analysis will be done for time to dialysis initiation or reaching the composite endpoint [>50% eGFR decline or initiation of maintenance dialysis treatment] including the same baseline variables as mentioned for the primary endpoint.

02

Conditions studied

03

In context

Kidney Diseases

3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.

This study's enrollment of 1,000 is above the median of 192 across 1,033 observational studies indexed under Kidney Diseases.

Browse Kidney Diseases studies →

Lead sponsor

Fresenius Kabi is the lead sponsor of 51 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Primary nephrologic care

Eligibility criteria

Inclusion Criteria:

  • Age >=20 years
  • Diagnosis of chronic kidney disease stage 3b to 5 (non-dialysis) according to KDIGO1, i.e. GFR \< 45 ml/min/1.73 m².
  • Regular dietetic consultancy (at least once a year) for patients with stages 4 and 5 (GFR \< 30 ml/min/1.73m²) who are following a LPD or sVLPD.
  • Written informed consent according to local regulations

Exclusion Criteria:Hypercalcemia

  • Disturbed amino acid metabolism, e.g. phenylketonuria
  • A kidney transplant
  • Sustained high blood pressure (inadequately controlled (>160 mmHg systolic or >110 mmHg diastolic) despite ≥3 antihypertensive medications)
  • Independent life-threatening disease(s), i.e. terminal cancer, AIDS, stage IV heart failure, end stage liver cirrhosis
  • Renal insufficiency caused by
  • Renal cancer
  • Genetic renal diseases, e.g. polycystic kidney disease, congenital nephrotic syndrome
  • Hypersensitivity to the active substances or to any of the excipients of the ketoanalogue supplement
  • Furthermore, pregnant and breast-feeding patients
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (actual)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • No protein restriction

    No protein restriction

  • Low protein diet (LPD)

    LPD: \< 0.8 g/kg bodyweight

  • Ketoanalogue suppl. very LPD

    sVLPD: 0.3-0.4 g/kg bodyweight + keotanalogues

06

What researchers measure

Primary outcomes

  1. Primary composite endpoint: 50 % eGFR decline or renal replacement therapy [Time Frame: From inclusion to 2 years follow up]

    Primary composite endpoint \[Time Frame: From inclusion/Patient enrolment to 2 years follow up\]. Need for renal replacement therapy or an at least 50% reduction in the estimated glomerular filtration rate (eGFR) compared to time of patient inclusion into the study and after 2 years

    Time frame: 2 years

Secondary outcomes

  1. Prescribed diet

    Prescribed diet (no protein restriction, low protein diet, supplemented very low protein diet), 2 years

    Time frame: 2 years

  2. Impact of compliance to prescribed protein diet on the eGRF decline

    Dietary compliance, 2 years, assessed by consulted dietitian (if available) estimating rated from 0 (not compliant) to 4 (fully compliant); 24 hours urine (if available, urinary urea excretion to assess the actual protein intake in comparison with the prescribed diet \[normal diet, LPD, sVLPD)

    Time frame: 2 years

07

Study locations

9 sites
  • Hualien Tzu Chi Hospital
    Hualien City, Hualien County 970, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung, Kaohsiung County 833, Taiwan
  • Keelung Chang Gung Memorial Hospital
    Keelung, Keeluing City 204;, Taiwan
  • Taipei Tzu Chi Hospital
    Taipei, New Taipei City 231, Taiwan
  • Shuang Ho Hospital
    Taipei, New Taipei City 235, Taiwan
  • Taichung Veterans General Hospital
    Taichung, Taichung City 407, Taiwan
  • National Cheng Kung University Hospital
    Tainan, Tainan County 704, Taiwan
  • Taipei Veterans General Hospital
    Taipe, Taipei City 112, Taiwan
  • Linkou Chang Gung Memorial Hospital
    Taoyuan, 333, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03619564
Lead sponsor
Fresenius Kabi
Responsible party
Sponsor
First posted
Aug 8, 2018
Start date
Aug 1, 2018
Primary completion
Sep 28, 2021
Completion
Sep 28, 2021
Last update
Feb 22, 2024

Study contacts

Hrishikesh Kulkarni, Dr.
study chair · Fresenius Kabi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion